5,5-dimethylcyclopent-1-enyl trifluoromethanesulfonate | 153580-03-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 5,5-dimethylcyclopent-1-enyl trifluoromethanesulfonate
• 英文别名: 5,5-dimethylcyclopent-1-en-1-yl trifluoromethanesulfonate；5,5-Dimethyl-1-cyclopentenyl trifluoromethanesulfonate；(5,5-dimethylcyclopenten-1-yl) trifluoromethanesulfonate
• CAS: 153580-03-1
• 化学式: C₈H₁₁F₃O₃S
• 分子量: 244.235
• InChiKey: SEAXRDLUZSGVKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5,5-dimethylcyclopent-1-enyl trifluoromethanesulfonate 在 platinum(IV) oxide 氢气 、 palladium diacetate 、 三乙胺 、 三苯基膦 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、137.9 kPa 条件下， 反应 0.75h， 生成 methyl 2,2-dimethylcyclopentane carboxylate
  参考文献：
  名称：

  .alpha.-Spirocyclopentyl- and .alpha.-spirocyclopropyl-.gamma.-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant .alpha.,.alpha.-disubstituted .gamma.-butyrolactones

  摘要：

  To further study the putative gamma-butyrolactone site of the GABA(A)/chloride channel complex, constrained derivatives of convulsant and anticonvulsant alpha,alpha-disubstituted gamma-butyrolactones (alpha-spirocyclopropyl- and alpha-spirocyclopentyl-gamma-butyrolactones) were synthesized and evaluated biologically. Most of the spirocyclopropyl agents were anticonvulsants when tested against pentylenetetrazole-induced seizures in mice. These agents effectively displaced (35)[S]-tert-butylbicyclophosphorothionate ((35)[S] -TBPS), a ligand for the picrotoxin binding site of the GABA(A)/chloride channel, from rat neuronal membranes and affected the GABA-mediated current in hippocampal neurons. The monomethyl-substituted spirocyclopropyl agent with a methyl group cis to the carbonyl (15) potentiates GABA-induced current whereas the trans derivative (16) blocks the current. The only anticonvulsant in the spirocyclopentyl series was the unsubstituted spirocyclopentyl compound 2. All the other substituted spirocyclopentyl targets were inactive in vivo at the highest dose tested except for convulsant 9, which has a trans 2,5-dimethyl-substituted cyclopentyl ring. All the spirocyclopentyl derivatives displaced (35)[S]-TBPS from rat neuronal membranes very effectively, and they also all potentiated GABA-induced chloride current except for convulsant 9 which blocked the current. From the data obtained in this investigation, it appears that when the volume occupied above and below the lactone ring is as large as that occupied by spirocyclopentyl agent 9, convulsant activity is observed. Groups with less volume in these areas either are inactive in the behavioral test or have anticonvulsant activity. When bound to the GABA(A)/chloride channel, the larger molecules may stabilize the closed state of the channel whereas the smaller molecules may stabilize the open state.

  DOI：

  10.1021/jm00028a011
• 作为产物：
  描述：

  5-氯-2,2-二甲基戊腈 在 正己基锂 、 sodium iodide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 、 丙酮 为溶剂， 反应 23.08h， 生成 5,5-dimethylcyclopent-1-enyl trifluoromethanesulfonate
  参考文献：
  名称：

  苯酚定向烯烃加氢催化不对称合成叔丁基碳中心

  摘要：

  据报道，一种快速合成的手性酚1的合成方法是制备一系列候选药物的关键组成部分。该策略包括从异丁腈（10）到环戊酮3的经济高效且易于扩展的途径。随后在由LaCl 3 ·2LiCl介导的具有挑战性的格利雅（Grignard）加成中使用了位阻和可烯醇化的酮3。描述了该转化所需的镧系元素试剂的新颖制备。为了完成该过程，高度对映选择性的氢化步骤提供了靶标（1）。讨论了酚基对不对称转化成功的重要性。

  DOI：

  10.1021/jo200941r

文献信息

• [EN] INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012072691A1

  公开（公告）日：2012-06-07

  The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有式(I)定义的化合物，其中变量R1、R2、R3、m和n如权利要求1中定义，具有宝贵的药理活性。特别是，这些化合物是GPR40受体的激动剂，因此适合用于治疗和预防可以通过这种受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。
• PYRROLIDINE GPR40 MODULATORS
  申请人：Ellsworth Bruce A.

  公开号：US20110082165A1

  公开（公告）日：2011-04-07

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物： 或其立体异构体，或药用可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• Rh₂(II)-Catalyzed Intramolecular Aliphatic C–H Bond Amination Reactions Using Aryl Azides as the N-Atom Source
  作者：Quyen Nguyen、Ke Sun、Tom G. Driver

  DOI：10.1021/ja301519q

  日期：2012.5.2

  Rhodium(II) dicarboxylate complexes were discovered to catalyze the intramolecular amination of unactivated primary, secondary, or tertiary aliphatic C-H bonds using aryl azides as the N-atom precursor. While a strong electron-withdrawing group on the nitrogen atom is typically required to achieve this reaction, we found that both electron-rich and electron-poor aryl azides are efficient sources for

  发现二羧酸铑 (II) 配合物使用芳基叠氮化物作为 N 原子前体催化未活化的伯、仲或叔脂肪族 CH 键的分子内胺化。虽然通常需要氮原子上的强吸电子基团来实现该反应，但我们发现富电子和缺电子芳基叠氮化物都是金属氮烯反应中间体的有效来源。
• [EN] CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS<br/>[FR] DÉRIVÉS D'ACIDE CARBOXYLIQUE CONFORMATIONNELLEMENT DÉPENDANTS, UTILES DANS LE TRAITEMENT DE TROUBLES DU MÉTABOLISME
  申请人：AMGEN INC

  公开号：WO2009111056A1

  公开（公告）日：2009-09-11

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了用于治疗主体内的代谢紊乱的化合物，例如，II型糖尿病。这些化合物具有通用公式I或通用公式III：其中变量的定义如下。本发明还提供了包括这些化合物的组合物，以及用于制备药物和治疗代谢紊乱如II型糖尿病的方法。
• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS PYRROLIDINES DE GPR40
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014078609A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体，或其药物可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。